Education
About Us
Working with TipRanks
Follow Us
Spago Nanomedical AB (SE:SPAGO)
:SPAGO
RESEARCH TOOLSreports
Top Page
Spago Nanomedical AB
(Frankfurt:SPAGO)
38Underperform
Spago Nanomedical AB (SPAGO) vs. S&P 500 (SPY)
Market Cap
kr66.16M
Dividend YieldN/A
Average Volume (3M)31.87K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue Growth58.72%
EPS Growth70.69%
CountrySE
Employees13
SectorHealthcare
Sector Strength39
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding348,196,200
10 Day Avg. Volume35,449
30 Day Avg. Volume31,872
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)-0.03
Price to Sales (P/S)0.00
P/FCF Ratio-2.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Spago Nanomedical AB Business Overview & Revenue Model
Company DescriptionSpago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.
How the Company Makes MoneySpago Nanomedical AB generates revenue through the development and commercialization of its nanomedical products, particularly in the oncology space. The company's primary revenue streams include licensing agreements, research and development partnerships, and potential future sales of its nanomedical solutions. Additionally, Spago Nanomedical collaborates with pharmaceutical companies and research institutions, which can provide funding and support for its projects. Revenue is also derived from grants and governmental or institutional funding aimed at advancing innovative cancer treatments and diagnostic tools.
Spago Nanomedical AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.91M | 1.20M | 1.05M | 660.00K | 342.00K | Gross Profit |
| -12.36M | -23.28M | -15.60M | -16.78M | -416.00K | EBIT |
| -33.71M | -42.51M | -39.47M | -39.19M | -18.96M | EBITDA |
| -33.40M | -42.22M | -38.73M | -38.69M | -18.59M | Net Income Common Stockholders |
| -32.51M | -42.22M | -39.31M | -39.08M | -18.90M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 32.47M | 45.22M | 62.10M | 52.46M | 28.45M | Total Assets |
| 39.58M | 52.98M | 205.95M | 191.62M | 162.82M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -32.47M | -45.22M | -62.10M | -52.46M | -28.45M | Total Liabilities |
| 2.28B | 11.67M | 8.80M | 6.81M | 3.15M | Stockholders Equity |
| -2.24B | 41.32M | 197.16M | 184.81M | 159.67M |
| Cash Flow | Free Cash Flow | |||
| -34.67M | -45.41M | -42.02M | -40.20M | -25.15M | Operating Cash Flow |
| -34.67M | -44.91M | -38.19M | -35.57M | -18.77M | Investing Cash Flow |
| -230.00K | -506.00K | -3.83M | -4.63M | -6.38M | Financing Cash Flow |
| 22.15M | 28.53M | 51.66M | 64.21M | 41.45M |
Spago Nanomedical AB Technical Analysis
Negative
0.19
Price Trends
0.21
Negative
0.21
Negative
0.23
Negative
Market Momentum
>-0.01
Positive
45.69
Neutral
32.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPAGO, the sentiment is Negative. The current price of 0.19 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.21, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.69 is Neutral, neither overbought nor oversold. The STOCH value of 32.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SPAGO.
Spago Nanomedical AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.14B | 3.39 | -43.55% | 2.83% | 16.49% | -0.19% | |
52 Neutral | kr48.71M | ― | -47.01% | ― | -94.12% | -25.83% | |
42 Neutral | kr48.52M | ― | -152.99% | ― | ― | 58.36% | |
41 Neutral | kr52.71M | ― | -59.73% | ― | ― | 45.38% | |
40 Underperform | kr50.56M | ― | -55.35% | ― | -57.26% | 72.71% | |
38 Underperform | kr66.16M | ― | -105.78% | ― | 58.72% | 70.69% |
* Healthcare Sector Average
Performance Comparison
SE:SPAGO
Spago Nanomedical AB
0.19
-0.08
-30.11%
SE:COMBI
CombiGene AB
2.46
-0.79
-24.31%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
18.52
-30.09
-61.90%
SE:MODTX
Modus Therapeutics Holding AB
1.39
0.30
28.24%
SE:ONCOZ
OncoZenge AB
5.26
1.55
41.78%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.